BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

CME Activities

• Relapsed/Refractory Mantle Cell Lymphoma: How Would You Care for These Virtual Patients?
  Medscape Education Oncology, September 2023
  Did you know that multiple treatment options are available for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of therapy?
  1.00 CME

  1.00 ABIM MOC
• Clinical Decision-Making in Relapsed/Refractory Mantle Cell Lymphoma: Test Your Skills
  Medscape Education Oncology, June 2023
  Did you know that there are multiple treatment options available in the third-line setting for relapsed/refractory (R/R) mantle cell lymphoma (MCL)?
  1.00 CME

  1.00 ABIM MOC
• Let's Talk Relapsed/Refractory Chronic Lymphocytic Leukemia: Expert Perspectives on Reversible BTK Inhibitors
  Medscape Education Oncology, April 2023
  Did you know studies have shown that noncovalent BTK inhibitors are efficacious in patients with covalent BTK inhibitor-pretreated CLL?
  0.25 CME

  0.25 ABIM MOC
• Relapsed/Refractory Mantle Cell Lymphoma: Where Do Novel BTK Inhibitors Fit for Our Patients?
  Medscape Education Oncology, March 2023
  Have you heard about the newest noncovalent Bruton tyrosine kinase (BTK) inhibitor that has been added to the selection of BTK inhibitors used to treat relapsed/refractory (R/R) mantle cell lymphoma (MCL)?
  0.50 CME
• BTK Inhibitors for CLL and MCL: What the Latest Data Mean for Our Patients
  Medscape Education Oncology, March 2023
  Did you know noncovalent BTK inhibitor therapy is now an option for patients with pretreated MCL who fail a prior covalent BTK inhibitor therapy?
  0.75 CME

  0.75 ABIM MOC
• The New Climate of Bruton Tyrosine Kinase Inhibitors: Winter Meeting Effects on the Management of CLL and MCL
  Medscape Education, December 2022
  Did you know that the second-generation Bruton tyrosine kinase (BTK) inhibitors will likely be the new standard of care when used as monotherapy?
  0.50 CME

  0.50 ABIM MOC
• BTK Inhibitors for CLL and MCL: A Settling Storm or Just the Beginning?
  Medscape Education Oncology, December 2022
  Did you know that emerging noncovalent BTK inhibitors could fill the gap for patients with B-cell malignancies who fail covalent BTK inhibitors?
  0.50 CME

  0.50 ABIM MOC
• Winter Conference Forecast for CLL and MCL: An Expert Exchange on Bruton Tyrosine Kinase Inhibitors
  Medscape Education, December 2022
  Did you know that exciting data on covalent and non-covalent Bruton tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are being presented at the upcoming winter conference?
  0.25 CME
• Relapsed/Refractory Mantle Cell Lymphoma and BTK Inhibitors: Expert Exchange and Discussion
  Medscape Education Oncology, November 2022
  Did you know that the emerging non-covalent BTK inhibitors reversibly bind to BTK?
  0.50 CME

  0.50 ABIM MOC
• Relapsed/Refractory Chronic Lymphocytic Leukemia and BTK Inhibitors
  Medscape Education Oncology, November 2022
  Did you know that Bruton tyrosine kinase (BTK) C481 mutations are the dominant reason for progressive chronic lymphocytic leukemia (CLL) after covalent BTK inhibitors?
  0.50 CME

  0.50 ABIM MOC
• Are We Ready for More BTK Inhibitors in Chronic Lymphocytic Leukemia? Experts Discuss the Latest Data
  Medscape Education, August 2022
  Did you know that noncovalent Bruton tyrosine kinase (BTK) inhibitors are a potential solution to overcome the challenge of covalent BTK inhibitor resistance in chronic lymphocytic leukemia (CLL)?
  0.50 CME

  0.50 ABIM MOC
• Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Context and Impact of New Data
  Medscape Education Oncology, April 2022
  Did you know that noncovalent BTK inhibitors are potentially the answer to the development of resistance to covalent BTK inhibitors?
  0.50 CME

  0.50 ABIM MOC